CTLA4 and head and neck squamous cell carcinoma: Synergy between evofosfamide and ICI has been observed in other tumour models, including HNSCC, where combination evofosfamide and anti-CTLA-4 significantly improved survival compared to anti-CTLA-4 alone [155].